Recent advances in uveal melanoma treatment
- PMID: 28759124
- DOI: 10.1002/med.21460
Recent advances in uveal melanoma treatment
Abstract
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Recent advances in the understanding of molecular characteristics helped to determine which tumors are most likely to progress. About 50% of patients carrying genetic alterations such as chromosomal aberrations and mutations are at significant risk for metastatic disease of which the majority will succumb to UM within few months. Currently, there is no effective treatment for metastatic uveal melanoma, and we hope this review will encourage researchers and clinicians to work to find a better standard of care. In this article we provide a comprehensive overview of the molecular framework of UM, highlighting the most common mutations involved in this kind of cancer. It also covers the most recent treatments from basic research to clinical trials, including small molecules, nucleic acids or immunotherapy, among others. It is intended to serve as a key reference for clinicians and researchers working in this field.
Keywords: MAPK pathway; PI3K pathway; cancer; melanoma; uveal melanoma.
© 2017 Wiley Periodicals, Inc.
Similar articles
-
Update on Metastatic Uveal Melanoma: Progress and Challenges.BioDrugs. 2016 Jun;30(3):161-72. doi: 10.1007/s40259-016-0167-4. BioDrugs. 2016. PMID: 27000042 Review.
-
Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations.Pigment Cell Melanoma Res. 2024 May;37(3):411-425. doi: 10.1111/pcmr.13161. Epub 2024 Feb 27. Pigment Cell Melanoma Res. 2024. PMID: 38411373 Review.
-
Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review.Clin Exp Ophthalmol. 2016 Aug;44(6):509-19. doi: 10.1111/ceo.12688. Epub 2016 Feb 11. Clin Exp Ophthalmol. 2016. PMID: 26601795 Review.
-
The genetics of uveal melanoma: an emerging framework for targeted therapy.Pigment Cell Melanoma Res. 2012 Mar;25(2):171-81. doi: 10.1111/j.1755-148X.2012.00979.x. Epub 2012 Feb 13. Pigment Cell Melanoma Res. 2012. PMID: 22268848 Free PMC article. Review.
-
Recent approaches for the treatment of uveal melanoma: Opportunities and challenges.Crit Rev Oncol Hematol. 2024 Jan;193:104218. doi: 10.1016/j.critrevonc.2023.104218. Epub 2023 Nov 30. Crit Rev Oncol Hematol. 2024. PMID: 38040071 Review.
Cited by
-
Elaiophylin Inhibits Tumorigenesis of Human Uveal Melanoma by Suppressing Mitophagy and Inducing Oxidative Stress via Modulating SIRT1/FoxO3a Signaling.Front Oncol. 2022 Mar 21;12:788496. doi: 10.3389/fonc.2022.788496. eCollection 2022. Front Oncol. 2022. PMID: 35387119 Free PMC article.
-
Magnetic nanoparticles in theranostics of malignant melanoma.EJNMMI Res. 2021 Dec 14;11(1):127. doi: 10.1186/s13550-021-00868-6. EJNMMI Res. 2021. PMID: 34905138 Free PMC article. Review.
-
Artesunate combined with verteporfin inhibits uveal melanoma by regulation of the MALAT1/yes-associated protein signaling pathway.Oncol Lett. 2021 Aug;22(2):597. doi: 10.3892/ol.2021.12858. Epub 2021 Jun 9. Oncol Lett. 2021. PMID: 34188699 Free PMC article.
-
SKP2 targeted inhibition suppresses human uveal melanoma progression by blocking ubiquitylation of p27.Onco Targets Ther. 2019 May 30;12:4297-4308. doi: 10.2147/OTT.S203888. eCollection 2019. Onco Targets Ther. 2019. PMID: 31213847 Free PMC article.
-
Acetylsalicylic Acid Exerts Potent Antitumor and Antiangiogenic Effects in Cutaneous and Uveal Melanoma Cell Lines.Ocul Oncol Pathol. 2020 Dec;6(6):442-455. doi: 10.1159/000510582. Epub 2020 Nov 4. Ocul Oncol Pathol. 2020. PMID: 33447595 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical